{"id":"floxuridine","rwe":[{"pmid":"41872621","year":"2026","title":"Hepatic Artery Infusion Pump Chemotherapy Associated Biliary Sclerosis After Treatment for Colorectal Cancer Liver Metastasis.","finding":"","journal":"Annals of surgical oncology","studyType":"Clinical Study"},{"pmid":"41685147","year":"2026","title":"Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma.","finding":"","journal":"Acta pharmaceutica Sinica. B","studyType":"Clinical Study"},{"pmid":"41563534","year":"2026","title":"Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic Factors.","finding":"","journal":"Journal of gastrointestinal cancer","studyType":"Clinical Study"},{"pmid":"41474237","year":"2025","title":"Hepatic artery infusion chemotherapy for liver metastases in small cell lung cancer.","finding":"","journal":"Journal of cancer research and therapeutics","studyType":"Clinical Study"},{"pmid":"41344085","year":"2026","title":"Establishment of a stable replicon cell line of Tembusu virus (TMUV) for high-throughput antiviral screening.","finding":"","journal":"Poultry science","studyType":"Clinical Study"}],"_fda":{"id":"42039e70-fc10-450f-9dec-2b0402160bda","set_id":"4681f23e-6b5e-433b-b245-3d0b4e64ebb2","openfda":{"nui":["N0000180853","M0006020"],"unii":["039LU44I5M"],"route":["INTRA-ARTERIAL"],"rxcui":["310351"],"spl_id":["42039e70-fc10-450f-9dec-2b0402160bda"],"brand_name":["Floxuridine"],"spl_set_id":["4681f23e-6b5e-433b-b245-3d0b4e64ebb2"],"package_ndc":["81643-9270-1"],"product_ndc":["81643-9270"],"generic_name":["FLOXURIDINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Deoxyuridine [CS]"],"substance_name":["FLOXURIDINE"],"pharm_class_epc":["Antimetabolite [EPC]"],"manufacturer_name":["JND Therapeutics, Inc."],"application_number":["ANDA075387"],"is_original_packager":[true]},"version":"7","warnings":["WARNINGS BECAUSE OF THE POSSIBILITY OF SEVERE TOXIC REACTIONS, ALL PATIENTS SHOULD BE HOSPITALIZED FOR THE FIRST COURSE OF THERAPY. Floxuridine should be used with extreme caution in poor risk patients with impaired hepatic or renal function or a history of high-dose pelvic irradiation or previous use of alkylating agents. The drug is not intended as an adjuvant to surgery. Floxuridine may cause fetal harm when administered to a pregnant woman. It has been shown to be teratogenic in the chick embryo, mouse (at doses of 2.5 to 100 mg/kg) and rat (at doses of 75 to 150 mg/kg). Malformations included cleft palates; skeletal defects; and deformed appendages, paws and tails. The dosages which were teratogenic in animals are 4.2 to 125 times the recommended human therapeutic dose. There are no adequate and well-controlled studies with floxuridine in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking (receiving) this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. Combination Therapy Any form of therapy which adds to the stress of the patient, interferes with nutrition or depresses bone marrow function will increase the toxicity of floxuridine."],"pregnancy":["Pregnancy Teratogenic Effects: Pregnancy Category D See WARNINGS section. Floxuridine has been shown to be teratogenic in the chick embryo, mouse (at doses of 2.5 to 100 mg/kg) and rat (at doses of 75 to 150 mg/kg). Malformations included cleft palates, skeletal defects and deformed appendages, paws and tails. The dosages which were teratogenic in animals were 4.2 to 125 times the recommended human therapeutic dose. There are no adequate and well-controlled studies with floxuridine in pregnant women. While there is no evidence of teratogenicity in humans due to floxuridine, it should be kept in mind that other drugs which inhibit DNA synthesis (e.g., methotrexate and aminopterin) have been reported to be teratogenic in humans. Floxuridine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects Floxuridine has not been studied in animals for its effects on peri- and postnatal development. However, compounds which inhibit DNA, RNA and protein synthesis might be expected to have adverse effects on peri- and postnatal development."],"overdosage":["OVERDOSAGE The possibility of overdosage with floxuridine is unlikely in view of the mode of administration. Nevertheless, the anticipated manifestations would be nausea, vomiting, diarrhea, gastrointestinal ulceration and bleeding, bone marrow depression (including thrombocytopenia, leukopenia and agranulocytosis). No specific antidotal therapy exists. Patients who have been exposed to an overdosage of floxuridine should be monitored hematologically for at least 4 weeks. Should abnormalities appear, appropriate therapy should be utilized. The acute intravenous toxicity of floxuridine is as follows: LD 50 Species (mg/kg ± S.E.) Mouse 880 ± 51 Rat 670 ± 73 Rabbit 94 ± 19.6 Dog 157 ± 46"],"references":["REFERENCES 1.Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC, US Government Printing Office, NIH publication 83-2621. 2.AMA Council Report. Guidelines for handling parenteral antineoplastics. JAMA . Mar 15, 1985, 253:1590-1592. 3.National Study Commission on Cytotoxic Exposure: Recommendation for handling cytotoxic agents. Available from Louis P. Jeffrey, ScD, Director of Pharmacy Services, Rhode Island Hospital, 593 Eddy Street, Providence, Rhode Island 02902. 4.Clinical Oncological Society of Australia: Guidelines and recommendations for safe handling of antineoplastic agents. Med J Aust . Apr 30, 1983, 1:426-428. 5.Jones, RB, Frank R, Mass T: Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. CA. Sept - Oct, 1983, 33:258-263. 6.American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. AM J Hosp Pharm 1990:47:1033-1049. 7.Controlling Occupational Exposure to Hazardous Drugs. (OSHA WORK-PRACTICE GUIDELINES). AM J Health-Syst Pharm . 1996:523:1669-1685"],"description":["DESCRIPTION Floxuridine for Injection, USP, an antineoplastic antimetabolite, is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. Each vial contains 500 mg of floxuridine which is to be reconstituted with 5 mL of sterile water for injection. An appropriate amount of reconstituted solution is then diluted with a parenteral solution for intra-arterial infusion (see DOSAGE AND ADMINISTRATION section). Floxuridine is a fluorinated pyrimidine. Chemically, floxuridine is 2'-Deoxy-5-fluorouridine, with a molecular formula of C 9 H 11 FN 2 O 5 . It is a white to off-white odorless solid which is freely soluble in water. The 2% aqueous solution has a pH of between 4.0 and 5.5. The molecular weight of floxuridine is 246.20 and the structural formula is: structural formula"],"precautions":["PRECAUTIONS General Floxuridine is a highly toxic drug with a narrow margin of safety. Therefore, patients should be carefully supervised since therapeutic response is unlikely to occur without some evidence of toxicity. Severe hematological toxicity, gastrointestinal hemorrhage and even death may result from the use of floxuridine despite meticulous selection of patients and careful adjustment of dosage. Although severe toxicity is more likely in poor risk patients, fatalities may be encountered occasionally even in patients in relatively good condition. Therapy is to be discontinued promptly whenever one of the following signs of toxicity appears: Myocardial ischemia Stomatitis or esophagopharyngitis, at the first visible sign Leukopenia (WBC under 3500) or a rapidly falling white blood count Vomiting, intractable Diarrhea, frequent bowel movements or watery stools Gastrointestinal ulceration and bleeding Thrombocytopenia (platelets under 100,000) Hemorrhage from any site Information for Patients Patients should be informed of expected toxic effects, particularly oral manifestations. Patients should be alerted to the possibility of alopecia as a result of therapy and should be informed that it is usually a transient effect. Laboratory Tests Careful monitoring of the white blood count and platelet count is recommended. Drug Interactions See WARNINGS section. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term studies in animals to evaluate the carcinogenic potential of floxuridine have not been conducted. On the basis of the available data, no evaluation can be made of the carcinogenic risk of floxuridine to humans. Mutagenesis Oncogenic transformation of fibroblasts from mouse embryo has been induced in vitro by floxuridine, but the relationship between oncogenicity and mutagenicity is not clear. Floxuridine has also been shown to be mutagenic in human leukocytes in vitro and in the Drosophila test system. In addition, 5-fluorouracil, to which floxuridine is catabolized when given by intra-arterial injection, has been shown to be mutagenic in in vitro tests. Impairment of Fertility The effects of floxuridine on fertility and general reproductive performance have not been studied in animals. However, because floxuridine is catabolized to 5-fluorouracil, it should be noted the 5-fluorouracil has been shown to induce chromosomal aberrations and changes in chromosome organization of spermatogonia in rats at doses of 125 or 250 mg/kg, administered intraperitoneally. Spermatogonial differentiation was also inhibited by fluorouracil, resulting in transient infertility. In female rats, fluorouracil, administered intraperitoneally at doses of 25 or 50 mg/kg during the preovulatory phase of oogenesis, significantly reduced the incidence of fertile matings, delayed the development of pre- and post-implantation embryos, increased the incidence of preimplantation lethality and induced chromosomal anomalies in these embryos. Compounds such as floxuridine, which interfere with DNA, RNA and protein synthesis, might be expected to have adverse effects on gametogenesis. Pregnancy Teratogenic Effects: Pregnancy Category D See WARNINGS section. Floxuridine has been shown to be teratogenic in the chick embryo, mouse (at doses of 2.5 to 100 mg/kg) and rat (at doses of 75 to 150 mg/kg). Malformations included cleft palates, skeletal defects and deformed appendages, paws and tails. The dosages which were teratogenic in animals were 4.2 to 125 times the recommended human therapeutic dose. There are no adequate and well-controlled studies with floxuridine in pregnant women. While there is no evidence of teratogenicity in humans due to floxuridine, it should be kept in mind that other drugs which inhibit DNA synthesis (e.g., methotrexate and aminopterin) have been reported to be teratogenic in humans. Floxuridine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects Floxuridine has not been studied in animals for its effects on peri- and postnatal development. However, compounds which inhibit DNA, RNA and protein synthesis might be expected to have adverse effects on peri- and postnatal development. Nursing Mothers It is not known whether floxuridine is excreted in human milk. Because floxuridine inhibits DNA and RNA synthesis, mothers should not nurse while receiving this drug. Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"how_supplied":["HOW SUPPLIED Floxuridine for Injection, USP, 500 mg, lyophilized, in a 5 mL vial, is supplied in individual cartons. NDC 81643-9270-1. This is to be reconstituted with 5 mL sterile water for injection. The sterile powder should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Reconstituted vials should be stored under refrigeration 2° to 8°C (36° to 46°F) for not more than 2 weeks. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 1-877-845-0689."],"boxed_warning":["WARNING It is recommended that floxuridine be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and intra-arterial drug therapy and is well versed in the use of potent antimetabolites. Because of the possibility of severe toxic reactions, all patients should be hospitalized for initiation of the first course of therapy."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20241007","nursing_mothers":["Nursing Mothers It is not known whether floxuridine is excreted in human milk. Because floxuridine inhibits DNA and RNA synthesis, mothers should not nurse while receiving this drug."],"laboratory_tests":["Laboratory Tests Careful monitoring of the white blood count and platelet count is recommended."],"overdosage_table":["
LD50
Species (mg/kg ± S.E.)
Mouse 880 ± 51
Rat 670 ± 73
Rabbit 94 ± 19.6
Dog 157 ± 46
"],"adverse_reactions":["ADVERSE REACTIONS Adverse reactions to the arterial infusion of floxuridine are generally related to the procedural complications of regional arterial infusion. The more common adverse reactions to the drug are nausea, vomiting, diarrhea, enteritis, stomatitis and localized erythema. The more common laboratory abnormalities are anemia, leukopenia, thrombo-cytopenia and elevations of alkaline phosphatase, serum transaminase, serum bilirubin and lactic dehydrogenase. Other adverse reactions are: Gastrointestinal: duodenal ulcer, duodenitis, gastritis, bleeding, gastroenteritis, glossitis, pharyngitis, anorexia, cramps, abdominal pain; possible intra- and extrahepatic biliary sclerosis, as well as acalculous cholecystitis. Dermatologic: alopecia, dermatitis, nonspecific skin toxicity, rash. Cardiovascular: myocardial ischemia. Miscellaneous Clinical Reactions: fever, lethargy, malaise, weakness. Laboratory Abnormalities: BSP, prothrombin, total proteins, sedimentation rate and thrombopenia. Procedural Complications of Regional Arterial Infusion: arterial aneurysm; arterial ischemia; arterial thrombosis; embolism; fibromyositis; thrombophlebitis; hepatic necrosis; abscesses; infection at catheter site; bleeding at catheter site; catheter blocked, displaced or leaking. The following adverse reactions have not been reported with floxuridine but have been noted following the administration of 5-fluorouracil. While the possibility of these occurring following floxuridine therapy is remote because of its regional administration, one should be alert for these reactions following the administration of floxuridine because of the pharmacological similarity of these two drugs: pancytopenia, agranulocytosis, myocardial ischemia, angina, anaphylaxis, generalized allergic reactions, acute cerebellar syndrome, nystagmus, headache, dry skin, fissuring, photosensitivity, pruritic maculopapular rash, increased pigmentation of the skin, vein pigmentation, lacrimal duct stenosis, visual changes, lacrimation, photophobia, disorientation, confusion, euphoria, epistaxis and nail changes, including loss of nails."],"contraindications":["CONTRAINDICATIONS Floxuridine therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections."],"drug_interactions":["Drug Interactions See WARNINGS section."],"general_precautions":["General Floxuridine is a highly toxic drug with a narrow margin of safety. Therefore, patients should be carefully supervised since therapeutic response is unlikely to occur without some evidence of toxicity. Severe hematological toxicity, gastrointestinal hemorrhage and even death may result from the use of floxuridine despite meticulous selection of patients and careful adjustment of dosage. Although severe toxicity is more likely in poor risk patients, fatalities may be encountered occasionally even in patients in relatively good condition. Therapy is to be discontinued promptly whenever one of the following signs of toxicity appears: Myocardial ischemia Stomatitis or esophagopharyngitis, at the first visible sign Leukopenia (WBC under 3500) or a rapidly falling white blood count Vomiting, intractable Diarrhea, frequent bowel movements or watery stools Gastrointestinal ulceration and bleeding Thrombocytopenia (platelets under 100,000) Hemorrhage from any site"],"teratogenic_effects":["Teratogenic Effects: Pregnancy Category D See WARNINGS section. Floxuridine has been shown to be teratogenic in the chick embryo, mouse (at doses of 2.5 to 100 mg/kg) and rat (at doses of 75 to 150 mg/kg). Malformations included cleft palates, skeletal defects and deformed appendages, paws and tails. The dosages which were teratogenic in animals were 4.2 to 125 times the recommended human therapeutic dose. There are no adequate and well-controlled studies with floxuridine in pregnant women. While there is no evidence of teratogenicity in humans due to floxuridine, it should be kept in mind that other drugs which inhibit DNA synthesis (e.g., methotrexate and aminopterin) have been reported to be teratogenic in humans. Floxuridine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY When floxuridine is given by rapid intra-arterial injection it is apparently rapidly catabolized to 5-fluorouracil. Thus, rapid injection of floxuridine produces the same toxic and antimetabolic effects as does 5-fluorouracil. The primary effect is to interfere with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibit the formation of ribonucleic acid (RNA). However, when floxuridine is given by continuous intra-arterial infusion its direct anabolism to floxuridine-monophosphate is enhanced, thus increasing the inhibition of DNA. Floxuridine is metabolized in the liver. The drug is excreted intact and as urea, fluorouracil, a-fluoro-b-ureidopropionic acid, dihydrofluorouracil, a-fluoro-b-guanidopropionic acid and a-fluoro-b-alanine in the urine; it is also expired as respiratory carbon dioxide. Pharmacokinetic data on intra-arterial infusion of floxuridine are not available."],"indications_and_usage":["INDICATIONS AND USAGE Floxuridine for Injection, USP is effective in the palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Patients with known disease extending beyond an area capable of infusion via a single artery should, except in unusual circumstances, be considered for systemic therapy with other chemotherapeutic agents."],"nonteratogenic_effects":["Nonteratogenic Effects Floxuridine has not been studied in animals for its effects on peri- and postnatal development. However, compounds which inhibit DNA, RNA and protein synthesis might be expected to have adverse effects on peri- and postnatal development."],"information_for_patients":["Information for Patients Patients should be informed of expected toxic effects, particularly oral manifestations. Patients should be alerted to the possibility of alopecia as a result of therapy and should be informed that it is usually a transient effect."],"spl_unclassified_section":["FOR INTRA-ARTERIAL INFUSION ONLY Rx only WARNING It is recommended that floxuridine be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and intra-arterial drug therapy and is well versed in the use of potent antimetabolites. Because of the possibility of severe toxic reactions, all patients should be hospitalized for initiation of the first course of therapy.","Distributed by JND Therapeutics Newton, MA 02459 USA Manufactured by THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany Revised January 2024 127.207.046/02"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Each vial must be reconstituted with 5 mL of sterile water for injection to yield a solution containing approximately 100 mg of floxuridine/mL. The calculated daily dose(s) of the drug is then diluted with 5% dextrose or 0.9% sodium chloride injection to a volume appropriate for the infusion apparatus to be used. The administration of floxuridine is best achieved with the use of an appropriate pump to overcome pressure in large arteries and to ensure a uniform rate of infusion. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. The recommended therapeutic dosage schedule of floxuridine by continuous arterial infusion is 0.1 to 0.6 mg/kg/day. The higher dosage ranges (0.4 to 0.6 mg) are usually employed for hepatic artery infusion because the liver metabolizes the drug, thus reducing the potential for systemic toxicity. Therapy can be given until adverse reactions appear. (See PRECAUTIONS section.) When these side effects have subsided, therapy may be resumed. The patient should be maintained on therapy as long as response to floxuridine continues. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1-7 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate."],"spl_product_data_elements":["Floxuridine Floxuridine FLOXURIDINE FLOXURIDINE WATER"],"package_label_principal_display_panel":["VIAL LABEL NDC 81643-9270-1 Rx only Floxuridine for Injection, USP 500 mg per vial FOR INTRA-ARTERIAL USE ONLY 5 mL Vial unit"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term studies in animals to evaluate the carcinogenic potential of floxuridine have not been conducted. On the basis of the available data, no evaluation can be made of the carcinogenic risk of floxuridine to humans. Mutagenesis Oncogenic transformation of fibroblasts from mouse embryo has been induced in vitro by floxuridine, but the relationship between oncogenicity and mutagenicity is not clear. Floxuridine has also been shown to be mutagenic in human leukocytes in vitro and in the Drosophila test system. In addition, 5-fluorouracil, to which floxuridine is catabolized when given by intra-arterial injection, has been shown to be mutagenic in in vitro tests. Impairment of Fertility The effects of floxuridine on fertility and general reproductive performance have not been studied in animals. However, because floxuridine is catabolized to 5-fluorouracil, it should be noted the 5-fluorouracil has been shown to induce chromosomal aberrations and changes in chromosome organization of spermatogonia in rats at doses of 125 or 250 mg/kg, administered intraperitoneally. Spermatogonial differentiation was also inhibited by fluorouracil, resulting in transient infertility. In female rats, fluorouracil, administered intraperitoneally at doses of 25 or 50 mg/kg during the preovulatory phase of oogenesis, significantly reduced the incidence of fertile matings, delayed the development of pre- and post-implantation embryos, increased the incidence of preimplantation lethality and induced chromosomal anomalies in these embryos. Compounds such as floxuridine, which interfere with DNA, RNA and protein synthesis, might be expected to have adverse effects on gametogenesis."]},"tags":[{"label":"Antimetabolite","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Thymidylate synthase","category":"target"},{"label":"TYMS","category":"gene"},{"label":"L01BC09","category":"atc"},{"label":"Intra-Arterial","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Malignant neoplasm of liver","category":"indication"},{"label":"Primary malignant neoplasm of gastrointestinal tract","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antimetabolites, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING It is recommended that floxuridine be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and intra-arterial drug therapy and is well versed in the use of potent antimetabolites. Because of the possibility of severe toxic reactions, all patients should be hospitalized for initiation of the first course of therapy."],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"14 reports"},{"date":"","signal":"HEPATIC STEATOSIS","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"12 reports"},{"date":"","signal":"STEATOHEPATITIS","source":"FDA FAERS","actionTaken":"12 reports"},{"date":"","signal":"ALANINE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"10 reports"},{"date":"","signal":"TACHYCARDIA","source":"FDA FAERS","actionTaken":"9 reports"},{"date":"","signal":"ASPARTATE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"6 reports"}],"drugInteractions":[{"url":"/drug/cyp2c9-substrates","drug":"CYP2C9 Substrates","action":"Use caution","effect":"Strong CYP2C9 Inhibitors - CYP2C9 Substrates","source":"DrugCentral","drugSlug":"cyp2c9-substrates"}],"commonSideEffects":[{"effect":"photosensitivity","drugRate":"reported","severity":"unknown"},{"effect":"pruritic maculopapular rash","drugRate":"reported","severity":"unknown"},{"effect":"increased pigmentation of the skin","drugRate":"reported","severity":"unknown"},{"effect":"vein pigmentation","drugRate":"reported","severity":"unknown"},{"effect":"lacrimal duct stenosis","drugRate":"reported","severity":"unknown"},{"effect":"visual changes","drugRate":"reported","severity":"unknown"},{"effect":"lacrimation","drugRate":"reported","severity":"unknown"},{"effect":"photophobia","drugRate":"reported","severity":"unknown"},{"effect":"disorientation","drugRate":"reported","severity":"unknown"},{"effect":"confusion","drugRate":"reported","severity":"unknown"},{"effect":"euphoria","drugRate":"reported","severity":"unknown"},{"effect":"epistaxis","drugRate":"reported","severity":"unknown"},{"effect":"nail changes","drugRate":"reported","severity":"unknown"},{"effect":"myocardial ischemia","drugRate":"reported","severity":"unknown"},{"effect":"angina","drugRate":"reported","severity":"unknown"},{"effect":"anaphylaxis","drugRate":"reported","severity":"unknown"},{"effect":"generalized allergic reactions","drugRate":"reported","severity":"unknown"},{"effect":"acute cerebellar syndrome","drugRate":"reported","severity":"unknown"},{"effect":"nystagmus","drugRate":"reported","severity":"unknown"},{"effect":"headache","drugRate":"reported","severity":"unknown"},{"effect":"dry skin","drugRate":"reported","severity":"unknown"},{"effect":"fissuring","drugRate":"reported","severity":"unknown"},{"effect":"pancytopenia","drugRate":"reported","severity":"unknown"},{"effect":"agranulocytosis","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute hemorrhage","Acute infectious disease","Anemia","Bone marrow depression","Breastfeeding (mother)","Cholecystitis","Disease of liver","Esophagitis","Fibrosis of bile duct","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Hyperbilirubinemia","Kidney disease","Leukopenia","Liver function tests abnormal","Myocardial ischemia","Nutritional disorder","Persistent vomiting","Pharyngitis","Pregnancy, function","Stomatitis","Thrombocytopenic disorder"],"specialPopulations":{"Pregnancy":"Floxuridine has been shown to be teratogenic in the chick embryo, mouse (at doses of 2.5 to 100 mg/kg) and rat (at doses of 75 to 150 mg/kg). Malformations included cleft palates, skeletal defects and deformed appendages, paws and tails. The dosages which were teratogenic in animals were 4.2 to 125 times the recommended human therapeutic dose.There are no adequate and well-controlled studies with floxuridine in pregnant women.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLOXURIDINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:11:55.859697+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:12:01.897047+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:11:54.987869+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLOXURIDINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:12:02.400282+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:54.121511+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:54.121534+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING It is recommended that floxuridine be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and intra-arterial drug therapy and is well versed in the use of potent antimetabolites. Because of the possibility of severe toxic reactions, all patients should be hospitalized for initiation of the first course of therapy.","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:54.121542+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:12:03.865622+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL601287/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:03.102922+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA075387","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:54.121545+00:00"}},"allNames":"fudr","offLabel":[],"synonyms":["floxuridine","floxuridin","5-Fluorouracil deoxyriboside","5-Fluorodeoxyuridine"],"timeline":[{"date":"1970-12-18","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2000-04-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Floxuridine, also known as FUDR, is a small molecule antimetabolite drug that targets thymidylate synthase. It was originally developed and is currently owned by Hospira. FUDR is FDA-approved for treating malignant neoplasms of the liver and primary malignant neoplasms of the gastrointestinal tract. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include its potential for severe gastrointestinal and hematological toxicity.","approvals":[{"date":"1970-12-18","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Fudr","ecosystem":[{"indication":"Malignant neoplasm of liver","otherDrugs":[],"globalPrevalence":null},{"indication":"Primary malignant neoplasm of gastrointestinal tract","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Thymidylate synthase","novelty":"Follow-on","targets":[{"gene":"TYMS","source":"DrugCentral","target":"Thymidylate synthase","protein":"Thymidylate synthase"}],"modality":"Small Molecule","drugClass":"Antimetabolite [EPC]","explanation":"","oneSentence":"","technicalDetail":"Floxuridine acts as a competitive inhibitor of thymidylate synthase, which is a key enzyme in the thymidylate synthase reaction, a crucial step in DNA synthesis. By inhibiting this enzyme, Floxuridine effectively reduces the production of thymidine, a nucleotide required for DNA replication and cell division."},"commercial":{"launchDate":"1970","_launchSource":"DrugCentral (FDA 1970-12-18, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1184","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLOXURIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLOXURIDINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:29:32.043065","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:06.517604+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cytarabine","drugSlug":"cytarabine","fdaApproval":"1969-06-17","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fluorouracil","drugSlug":"fluorouracil","fdaApproval":"1962-04-25","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gemcitabine","drugSlug":"gemcitabine","fdaApproval":"1996-05-15","patentExpiry":"Jun 28, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"capecitabine","drugSlug":"capecitabine","fdaApproval":"1998-04-30","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azacitidine","drugSlug":"azacitidine","fdaApproval":"2004-05-19","patentExpiry":"May 14, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"decitabine","drugSlug":"decitabine","fdaApproval":"2006-05-02","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trifluridine","drugSlug":"trifluridine","fdaApproval":"1980-04-10","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"floxuridine","indications":{"approved":[{"name":"Malignant neoplasm of liver","source":"DrugCentral","snomedId":93870000,"regulator":"FDA","eligibility":"carefully selected patients who are considered incurable by surgery or other means, with known disease extending beyond an area capable of infusion via single artery should, except in unusual circumstances, be considered for systemic therapy with other chemotherapeutic agents"},{"name":"Primary malignant neoplasm of gastrointestinal tract","source":"DrugCentral","snomedId":363745004,"regulator":"FDA","eligibility":"not specified"}],"offLabel":[],"pipeline":[]},"currentOwner":"Hospira","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cytarabine","brandName":"cytarabine","genericName":"cytarabine","approvalYear":"1969","relationship":"same-class"},{"drugId":"fluorouracil","brandName":"fluorouracil","genericName":"fluorouracil","approvalYear":"1962","relationship":"same-class"},{"drugId":"gemcitabine","brandName":"gemcitabine","genericName":"gemcitabine","approvalYear":"1996","relationship":"same-class"},{"drugId":"capecitabine","brandName":"capecitabine","genericName":"capecitabine","approvalYear":"1998","relationship":"same-class"},{"drugId":"azacitidine","brandName":"azacitidine","genericName":"azacitidine","approvalYear":"2004","relationship":"same-class"},{"drugId":"decitabine","brandName":"decitabine","genericName":"decitabine","approvalYear":"2006","relationship":"same-class"},{"drugId":"trifluridine","brandName":"trifluridine","genericName":"trifluridine","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":["Metastatic Colorectal Carcinoma","Metastatic Malignant Neoplasm in the Liver","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma"],"enrollment":408,"completionDate":"2034-06-30"},{"nctId":"NCT05286814","phase":"PHASE2","title":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-24","conditions":["Metastatic Colorectal Cancer (Mcrc)","Intrahepatic Cholangiocarcinoma (Icc)","Intrahepatic Bile Duct Cancer","Colorectal Neoplasms","Colorectal Cancer","Cholangiocarcinoma","Bile Duct Neoplasms","Bile Duct Cancer","Adrenocortical Carcinoma (ACC)","Adrenal Cortical Carcinoma","Adrenal Gland Cancer","Adrenal Gland Neoplasms","Adrenal Cortex Neoplasms"],"enrollment":70,"completionDate":"2028-12-31"},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":["Colorectal Cancer","Cholangiocarcinoma"],"enrollment":35,"completionDate":"2024-06-27"},{"nctId":"NCT01815359","phase":"PHASE2","title":"ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-03","conditions":["Appendix Cancer","Colorectal Cancer"],"enrollment":292,"completionDate":"2026-09"},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":["Gestational Trophoblastic Neoplasia"],"enrollment":70,"completionDate":"2027-01-01"},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":["Colorectal Cancer Metastatic","Intrahepatic Cholangiocarcinoma"],"enrollment":80,"completionDate":"2030-02"},{"nctId":"NCT06313203","phase":"PHASE2","title":"HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-02-13","conditions":["Intrahepatic Cholangiocarcinoma","Chemotherapy Effect"],"enrollment":39,"completionDate":"2034-01"},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":["Colorectal Cancer","Liver Metastases","Colorectal Adenocarcinoma","Colorectal Cancer With Hepatic Metastases","Colorectal Carcinoma"],"enrollment":24,"completionDate":"2025-11-13"},{"nctId":"NCT04891289","phase":"PHASE2","title":"Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-07","conditions":["Intrahepatic Cholangiocarcinoma"],"enrollment":164,"completionDate":"2026-05"},{"nctId":"NCT01312857","phase":"PHASE2","title":"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-03-07","conditions":["Metastatic Colorectal Cancer"],"enrollment":75,"completionDate":"2024-07-15"},{"nctId":"NCT00492999","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-05","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":64,"completionDate":"2026-05"},{"nctId":"NCT03856658","phase":"PHASE2","title":"Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corewell Health West","startDate":"2019-02-05","conditions":["Pancreatic Adenocarcinoma","Liver Metastases"],"enrollment":14,"completionDate":"2025-12"},{"nctId":"NCT04251715","phase":"PHASE2","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-04-28","conditions":["Liver and Intrahepatic Bile Duct Carcinoma","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Intrahepatic Cholangiocarcinoma"],"enrollment":5,"completionDate":"2025-11-30"},{"nctId":"NCT00059930","phase":"PHASE1","title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":38,"completionDate":"2025-03-24"},{"nctId":"NCT06888063","phase":"PHASE2","title":"Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-11-20","conditions":["Intrahepatic Bile Duct Cancer","Intrahepatic Cholangiocarcinoma (Icc)","Intrahepatic Bile Duct Carcinoma","Intrahepatic Cholangiocarcinoma"],"enrollment":40,"completionDate":"2031-09"},{"nctId":"NCT00200200","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-11-19","conditions":["Hepatic Metastases","Colon Cancer","Rectal Cancer"],"enrollment":73,"completionDate":"2025-03-13"},{"nctId":"NCT01862315","phase":"PHASE2","title":"Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":["Intrahepatic Cholangiocarcinoma","Peripheral Cholangiocarcinoma","Cholangiolar Carcinoma","Cholangiocellular Carcinoma"],"enrollment":55,"completionDate":"2025-03-18"},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":["Colorectal Neoplasms","Floxuridine","Liver Metastases","Vascular Access Device"],"enrollment":306,"completionDate":"2035-01"},{"nctId":"NCT00410956","phase":"PHASE2","title":"Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-05-09","conditions":["Liver Cancer"],"enrollment":22,"completionDate":"2024-05-07"},{"nctId":"NCT04898504","phase":"PHASE2","title":"HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-08-23","conditions":["Colorectal Cancer","Liver Metastases","Chemotherapy Effect"],"enrollment":45,"completionDate":"2026-05"},{"nctId":"NCT05865925","phase":"PHASE1,PHASE2","title":"Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors","status":"ENROLLING_BY_INVITATION","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-04-22","conditions":["Advanced Solid Tumors"],"enrollment":78,"completionDate":"2024-10-30"},{"nctId":"NCT02102789","phase":"PHASE3","title":"A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Yuhong Li","startDate":"2014-03","conditions":["Metastatic Colorectal Cancer"],"enrollment":142,"completionDate":"2024-12"},{"nctId":"NCT03500874","phase":"PHASE3","title":"Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2018-05-28","conditions":["Colorectal Cancer","Liver Metastases","HAI"],"enrollment":92,"completionDate":"2021-08-31"},{"nctId":"NCT00019760","phase":"PHASE2","title":"Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1999-04","conditions":["Recurrent Colon Cancer","Liver Metastases","Stage IV Rectal Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer"],"enrollment":0,"completionDate":"2002-03"},{"nctId":"NCT04276090","phase":"NA","title":"Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Michael J Cavnar, MD","startDate":"2020-05-01","conditions":["Bile Duct Neoplasms","Colorectal Neoplasms"],"enrollment":21,"completionDate":"2022-06-14"},{"nctId":"NCT00587067","phase":"PHASE2","title":"A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-06","conditions":["Hepatic Cancer"],"enrollment":34,"completionDate":"2016-05-19"},{"nctId":"NCT03678428","phase":"PHASE3","title":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2021-12-31","conditions":["Metastatic Colorectal Cancer","Liver Metastases"],"enrollment":92,"completionDate":"2022-12-31"},{"nctId":"NCT03493061","phase":"PHASE2","title":"A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-02-01","conditions":["Colo-rectal Cancer","Liver Metastases"],"enrollment":60,"completionDate":"2022-12-30"},{"nctId":"NCT01525069","phase":"PHASE1","title":"Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-04-03","conditions":["Cholangiocarcinoma","Liver Neoplasms"],"enrollment":27,"completionDate":"2022-08-02"},{"nctId":"NCT04511793","phase":"NA","title":"Hepatic Artery Infusion (HAI) Program at Duke University","status":"WITHDRAWN","sponsor":"Michael Lidsky, M.D.","startDate":"2020-12-11","conditions":["Metastatic Colon Cancer","Liver Cancer","Intrahepatic Cholangiocarcinoma"],"enrollment":0,"completionDate":"2022-12-31"},{"nctId":"NCT00361842","phase":"PHASE2","title":"Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2006-07","conditions":["Colorectal Neoplasms"],"enrollment":65,"completionDate":"2008-12"},{"nctId":"NCT00695201","phase":"PHASE1","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":["Colon Cancer","Rectal Cancer"],"enrollment":52,"completionDate":"2021-06-28"},{"nctId":"NCT04668976","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Benaroya Research Institute","startDate":"2020-11-25","conditions":["Colorectal Cancer","Cholangiocarcinoma"],"enrollment":100,"completionDate":"2024-12"},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":["Urothelial Carcinoma","Bladder Cancer","Urinary Bladder Neoplasms"],"enrollment":8,"completionDate":"2019-10-23"},{"nctId":"NCT04552093","phase":"PHASE2,PHASE3","title":"Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2020-09-09","conditions":["Colorectal Neoplasms"],"enrollment":31,"completionDate":"2022-12-31"},{"nctId":"NCT01938729","phase":"PHASE1","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-09-05","conditions":["Intrahepatic Cholangiocarcinoma","Peripheral Cholangiocarcinoma","Cholangiolar Carcinoma","Cholangiocellular Carcinoma) (ICC)"],"enrollment":8,"completionDate":"2020-09-10"},{"nctId":"NCT01749397","phase":"PHASE1","title":"Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-12-07","conditions":["Stage IV Fallopian Tube Cancer AJCC v6 and v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Primary Peritoneal Cancer AJCC v7"],"enrollment":29,"completionDate":"2019-11-21"},{"nctId":"NCT03069950","phase":"PHASE2","title":"Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-28","conditions":["Colorectal Adenocarcinoma Metastatic to the Liver"],"enrollment":0,"completionDate":"2019-05-16"},{"nctId":"NCT00645710","phase":"PHASE1,PHASE2","title":"Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2005-02-11","conditions":["Liver Metastases","Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer"],"enrollment":16,"completionDate":"2018-02-07"},{"nctId":"NCT03876574","phase":"PHASE1","title":"Hepatic Artery Infusion Pump for NPC Liver Metastases","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2011-01-01","conditions":["Nasopharyngeal Carcinoma","Neoplasm Metastasis","Liver"],"enrollment":16,"completionDate":"2017-12-31"},{"nctId":"NCT00004142","phase":"PHASE2","title":"Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1998-08-05","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":40,"completionDate":"2003-12-09"},{"nctId":"NCT00848783","phase":"PHASE2","title":"Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2008-05","conditions":["Gastric Cancer","Gastric Adenocarcinoma","Esophageal Cancer"],"enrollment":8,"completionDate":"2012-09"},{"nctId":"NCT00449163","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer","status":"TERMINATED","sponsor":"University of Miami","startDate":"2006-03-01","conditions":["Colorectal Cancer"],"enrollment":25,"completionDate":"2010-03"},{"nctId":"NCT00002842","phase":"PHASE2","title":"Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1994-09","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":49,"completionDate":"2014-05"},{"nctId":"NCT00448760","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-10","conditions":["Esophageal Cancer"],"enrollment":29,"completionDate":"2010-04"},{"nctId":"NCT00448682","phase":"PHASE2","title":"Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery","status":"TERMINATED","sponsor":"University of Miami","startDate":"2005-06","conditions":["Gastric Cancer"],"enrollment":25,"completionDate":"2010-03"},{"nctId":"NCT00002716","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1996-01","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":135,"completionDate":"2006-08"},{"nctId":"NCT00063960","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-08","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":94,"completionDate":"2004-12"},{"nctId":"NCT01692704","phase":"PHASE1,PHASE2","title":"Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2012-04","conditions":["Cholangiocellular Carcinoma"],"enrollment":12,"completionDate":"2016-03"},{"nctId":"NCT00858338","phase":"PHASE2","title":"Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2002-12","conditions":["Gastric Cancer","Stomach Cancer"],"enrollment":28,"completionDate":"2012-02"},{"nctId":"NCT02529774","phase":"PHASE2,PHASE3","title":"Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Ye Xu","startDate":"2015-09","conditions":["Resected Liver Metastases From Colorectal Cancer"],"enrollment":432,"completionDate":"2021-09"},{"nctId":"NCT02402972","phase":"PHASE3","title":"A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer","status":"UNKNOWN","sponsor":"Xu jianmin","startDate":"2015-02","conditions":["Colorectal Cancer","Metastasis"],"enrollment":700,"completionDate":"2022-02"},{"nctId":"NCT00183911","phase":"PHASE2","title":"Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2003-11","conditions":["Gastric Adenocarcinoma","Gastric Cancer"],"enrollment":25,"completionDate":"2007-04"},{"nctId":"NCT00408551","phase":"PHASE2","title":"Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver","status":"UNKNOWN","sponsor":"Goshen Health System","startDate":"2005-11","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":20,"completionDate":""},{"nctId":"NCT00026234","phase":"PHASE2","title":"Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-02","conditions":["Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum","Liver Metastases","Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer"],"enrollment":75,"completionDate":""},{"nctId":"NCT00002783","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1996-05","conditions":["Gastric Cancer"],"enrollment":50,"completionDate":"2001-01"},{"nctId":"NCT00003753","phase":"PHASE2","title":"Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-09","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":0,"completionDate":"2004-04"},{"nctId":"NCT00006038","phase":"PHASE2","title":"Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-02","conditions":["Esophageal Cancer","Gastric Cancer"],"enrollment":0,"completionDate":"2003-02"},{"nctId":"NCT00268463","phase":"PHASE3","title":"Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2006-01","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":22,"completionDate":"2008-06"},{"nctId":"NCT00008294","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00020501","phase":"PHASE3","title":"Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2001-03","conditions":["Colorectal Cancer","Metastatic Cancer"],"enrollment":0,"completionDate":"2005-01"},{"nctId":"NCT00005860","phase":"PHASE1","title":"Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-04","conditions":["Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00004103","phase":"PHASE2","title":"Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1998-07","conditions":["Gastric Cancer"],"enrollment":0,"completionDate":"2009-06"},{"nctId":"NCT00005049","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1997-05","conditions":["Colorectal Cancer","Gastric Cancer","Gastrointestinal Carcinoid Tumor","Gastrointestinal Stromal Tumor","Ovarian Cancer","Peritoneal Cavity Cancer","Small Intestine Cancer"],"enrollment":45,"completionDate":""},{"nctId":"NCT00643877","phase":"PHASE3","title":"Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-12","conditions":["Colorectal Neoplasms"],"enrollment":600,"completionDate":"2014-12"},{"nctId":"NCT00001576","phase":"PHASE1","title":"A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-07","conditions":["Colorectal Neoplasm","Liver Neoplasm","Neoplasm Metastasis"],"enrollment":28,"completionDate":"2002-03"},{"nctId":"NCT00001449","phase":"PHASE1","title":"A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-09","conditions":["Neoplasms"],"enrollment":60,"completionDate":"2000-04"},{"nctId":"NCT00522509","phase":"","title":"Preoperative Hepatic Arterial Infusion Chemotherapy","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"1995-12","conditions":["Colorectal Liver Metastases"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intra-Arterial","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRA-ARTERIAL","productName":"Floxuridine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146171","MMSL":"40527","NDDF":"002648","UNII":"039LU44I5M","VUID":"4017811","CHEBI":"CHEBI:60761","VANDF":"4017811","INN_ID":"2010","RXNORM":"4488","UMLSCUI":"C0016343","chemblId":"CHEMBL601287","ChEMBL_ID":"CHEMBL917","KEGG_DRUG":"D04197","DRUGBANK_ID":"DB00322","PUBCHEM_CID":"5790","SNOMEDCT_US":"387432008","IUPHAR_LIGAND_ID":"4801","MESH_DESCRIPTOR_UI":"D005467"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Pfizer","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"90%"},"publicationCount":514,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01BC09","allCodes":["L01BC09"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 23","pmid":"41872621","title":"Hepatic Artery Infusion Pump Chemotherapy Associated Biliary Sclerosis After Treatment for Colorectal Cancer Liver Metastasis.","journal":"Annals of surgical oncology"},{"date":"2026 Feb","pmid":"41685147","title":"Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma.","journal":"Acta pharmaceutica Sinica. B"},{"date":"2026 Jan 21","pmid":"41563534","title":"Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic Factors.","journal":"Journal of gastrointestinal cancer"},{"date":"2025 Dec 1","pmid":"41474237","title":"Hepatic artery infusion chemotherapy for liver metastases in small cell lung cancer.","journal":"Journal of cancer research and therapeutics"},{"date":"2026 Jan","pmid":"41344085","title":"Establishment of a stable replicon cell line of Tembusu virus (TMUV) for high-throughput antiviral screening.","journal":"Poultry science"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Am Regent","Fresenius Kabi Usa","Hikma"],"status":"approved","companyName":"Hospira","companyId":"","modality":"Small molecule","firstApprovalDate":"1970","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1970-12-18T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-07-01T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA075387"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-11-26T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA075837"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:06.517604+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}